• Please log in or register to access this feature.

Original Article

Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma†

  1. Meenu Jain PhD1,
  2. Lisa Zhang PhD1,
  3. Mei He MD1,
  4. Erin E. Patterson PhD1,
  5. Naris Nilubol MD1,
  6. Antonio T. Fojo MD, PhD3,
  7. Bharat Joshi PhD2,
  8. Raj Puri MD, PhD2,
  9. Electron Kebebew MD1,‡,*

Article first published online: 8 MAY 2012

DOI: 10.1002/cncr.27629

Issue

Cancer

Cancer

Volume 118, Issue 22, pages 5698–5708, 15 November 2012

Additional Information

How to Cite

Jain, M., Zhang, L., He, M., Patterson, E. E., Nilubol, N., Fojo, A. T., Joshi, B., Puri, R. and Kebebew, E. (2012), Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma. Cancer, 118: 5698–5708. doi: 10.1002/cncr.27629

Author Information

  1. 1

    Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

  2. 2

    Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland

  3. 3

    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

  1. ‡

    Fax: (301) 402-1788

*Endocrine Oncology Branch, National Cancer Institute, 10-CRC-Hatfield Clinical Research Center, 4-5952, Bethesda, MD 20892

  1. †

    This article is US Government work and, as such, is in the public domain in the United States of America.

  2. ‡

    Fax: (301) 402-1788

Publication History

  1. Issue published online: 30 OCT 2012
  2. Article first published online: 8 MAY 2012
  3. Manuscript Accepted: 27 MAR 2012
  4. Manuscript Revised: 6 MAR 2012
  5. Manuscript Received: 28 SEP 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (6507K)

Keywords:

  • interleukin-13 receptor alpha2;
  • interleuken-13-Pseudomonas exotoxin;
  • adrenocortical carcinoma;
  • invasion

Abstract

BACKGROUND.

Adrenocortical carcinoma (ACC) is a relatively rare but aggressive malignancy with limited therapeutic options. Previous genome-wide expression studies have demonstrated the overexpression of interleukin-13 receptor alpha2 (IL13Rα2) in some human malignancies.

METHODS.

The authors evaluated IL13Rα2 mRNA and protein expression in 21 normal samples, 78 benign samples, 10 primary malignant samples, and 25 metastatic/recurrent samples and performed functional analyses with IL13 ligand and IL13 Rα2 knockdown in vitro. The sensitivity of 2 ACC cell lines (NCI-H295R [high IL13Rα2 expression] and SW13 [low IL13Rα2 expression]) to a highly specific IL-13 conjugated with Pseudomonas exotoxin (IL-13-PE) also was evaluated in both in vitro and in vivo models.

RESULTS.

IL13Rα2 was overexpressed in malignant tumors compared with benign and normal samples (15-fold higher; P < .05). Immunohistochemistry also confirmed higher protein expression in malignant and benign tumors than in normal adrenocortical tissues (P < .05). The half-maximal inhibitory concentration for IL-13-PE was 1.3 ng/mL in the NCI-H295R cell line and 1000 ng/mL in the SW13 cell line. Mice that received intratumoral or intraperitoneal IL-13-PE injection had a significant reduction in tumor size and increased tumor necrosis compared with control groups (P < .05) and also had prolonged survival (P < .05). IL13Rα2 protein expression increased in cells that were treated with IL-13 ligand along with cell invasion (P < .05). Direct IL13Rα2 knockdown decreased cellular proliferation and invasion (P < .05).

CONCLUSIONS.

The current results indicated that IL13Rα2 is overexpressed in ACC and regulates cell invasion and proliferation. IL13Rα2 is a novel therapeutic target for the treatment of human ACC. Cancer 2012. © 2012 American Cancer Society.

View Full Article (HTML) Get PDF (6507K)